Zimbabwe has declined a significant American health deal worth 367 million US dollars (272 million pounds) over five years over Washington's insistence on sensitive information.
This move was revealed following a internal memorandum from December was disclosed, revealing that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
A government representative has since stated that the US was requesting health data for research and profit but was unwilling to guarantee the benefits from any future treatments.
"We will now turn to the challenging and unfortunate process of scaling back our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has urged continued negotiations to find a deal acceptable to both sides so the country's vital HIV treatment initiative can continue.
Wider Context
This rejection follows a similar situation in Kenya, where a high court suspended a similar health funding agreement following legal challenges were filed about the security of citizens' medical information.
After returning to office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
USAID had administered assistance for the US government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost openness and responsibility.
Based on reports, 16 nations in Africa have so far signed similar agreements, constituting more than $18.3bn in committed funds.
Details of the Declined Agreement
This assistance for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration could have provided immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children presently on HIV treatment through American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, with no corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that might result from that provided information," he stated.
"Put simply, our nation would supply the basic resources for medical research without any assurance that the end products would be available to our citizens should a future health crisis emerge."
Sovereignty and International Frameworks
Mangwana further pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were disrupting frameworks previously set up via the global health agency.
Mangwana cited its Pandemic Benefit-Sharing framework designed to deal with future global health emergencies.
"This mechanism is designed to ensure that when a nation provides its samples, the benefits – including medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
These objections over the US deal "should not be misconstrued as opposition to America," he added.
"We are open to ongoing dialogue with our US partners on how future collaboration could be arranged in a manner that honours the independence and interests of each country."
Medical Community Response
Medical experts stated it understood the government's concerns, but urged that talks need to persist considering a large portion of the nation's HIV programmes relied on foreign aid.
"In cases where technical issues arise, including those relating to data governance or implementation frameworks, these can frequently be addressed via technical clarification and negotiated safeguards," the group added.
The halted deal highlights the complex challenges between accepting crucial foreign assistance and protecting a country's data in an ever more data-driven world.